Lecanemab Slows Tau PET Accumulation
Arnaud Charil, Youfang Cao, Brian A Willis, Steven Hersch, Michael C Irizarry, Larisa Reyderman · 2025
Read Lecanemab Slows Tau PET Accumulation by Arnaud Charil, Youfang Cao, Brian A Willis, Steven Hersch, Michael C Irizarry, Larisa Reyderman (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713823.txt.
Description
Arnaud Charil and five co-authors report how a drug for early Alzheimer's disease affects tau, a protein that builds up in the sick brain. The drug, lecanemab, is an antibody that binds loose clumps of a second protein, amyloid. Their 2025 report draws on brain scans from a large trial of the drug.
Scans showed that tau built up more slowly in treated patients than in those on placebo, most of all in side regions of the brain. A math model of the disease was built to trace how tau grows over time. The model matched thirty months of trial data and suggested the drug can halt tau growth in a key memory region. The authors back longer treatment.
Catalog record
| CREATOR | Arnaud Charil, Youfang Cao, Brian A Willis, Steven Hersch, Michael C Irizarry, Larisa Reyderman |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |